Veredus Laboratories Launches VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 as CE-IVD Test Kit for Diagnostic Use across Europe
Veredus Laboratories Pte Ltd “Veredus” has received CE-IVD marking for VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 as a molecular diagnostic test kit to be used in clinical practice across Europe and other countries that recognize the CE Mark. This announcement follows the recent commercial launch of this IVD test with approvals from Health Sciences Authority (HSA) Singapore and Philippines FDA.
VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is a one-step Reverse Transcription Polymerase Chain Reaction (RT-PCR)-based IVD test intended for the qualitative detection of nucleic acid belonging to SARS-CoV-2.
“We are very pleased with the European launch of our test and for Veredus to reach out beyond South East Asia and into the European region to support countries in need for molecular test to detect and identify the SARS-CoV-2 virus. At the same time, with this CE-IVD marking, we can now plan for immediate rollout to healthcare institutions around the world for diagnostic use. Veredus is commited to join the fight against COVID-19 and will continue to help move precision testing forward,” said Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.